

REVIEW

Open Access

Applications and prospects of cryo-EM in drug discovery

Kong-Fu Zhu¹, Chuang Yuan², Yong-Ming Du³, Kai-Lei Sun⁴, Xiao-Kang Zhang^{5,6,7}, Horst Vogel⁸, Xu-Dong Jia⁹, Yuan-Zhu Gao¹⁰, Qin-Fen Zhang⁹, Da-Ping Wang^{1,11*} and Hua-Wei Zhang^{1,12*}

Abstract

Drug discovery is a crucial part of human healthcare and has dramatically benefited human lifespan and life quality in recent centuries, however, it is usually time- and effort-consuming. Structural biology has been demonstrated as a powerful tool to accelerate drug development. Among different techniques, cryo-electron microscopy (cryo-EM) is emerging as the mainstream of structure determination of biomacromolecules in the past decade and has received increasing attention from the pharmaceutical industry. Although cryo-EM still has limitations in resolution, speed and throughput, a growing number of innovative drugs are being developed with the help of cryo-EM. Here, we aim to provide an overview of how cryo-EM techniques are applied to facilitate drug discovery. The development and typical workflow of cryo-EM technique will be briefly introduced, followed by its specific applications in structure-based drug design, fragment-based drug discovery, proteolysis targeting chimeras, antibody drug development and drug repurposing. Besides cryo-EM, drug discovery innovation usually involves other state-of-the-art techniques such as artificial intelligence (AI), which is increasingly active in diverse areas. The combination of cryo-EM and AI provides an opportunity to minimize limitations of cryo-EM such as automation, throughput and interpretation of medium-resolution maps, and tends to be the new direction of future development of cryo-EM. The rapid development of cryo-EM will make it as an indispensable part of modern drug discovery.

Key words Cryo-electron microscopy (cryo-EM), Drug discovery, Structure-based drug design, Fragment-based drug discovery, Proteolysis targeting chimeras, Drug repurposing, Artificial intelligence (AI)

Background

Drug discovery is closely related to human health. Early drug discovery and development mainly stemmed from accidental discovery and natural product screening[1]. There are many interesting examples, including the discovery of the antibacterial activity of penicillin and sulfonamides, and the large-scale screening of natural products to identify the antitumor drug paclitaxel and the antimalarial drug artemisinin[2-5]. Since the late 20th century, breakthroughs in molecular biology, synthetic chemistry, structural biology, and computational techniques have brought great changes to the field of novel drug research and development[6]. The current drug design and discovery process is more directional and visible and requires a high degree of joint effort across multiple disciplines[7]. With further improvements in drug development strategies, new drug screening platforms have emerged based on traditional technologies. Presently, several of the most prevalent drug screening methods include the high-

throughput screening of compound libraries and technologies such as structure-based drug design (SBDD), fragment-based drug discovery (FBDD), DNA-encoded chemical library, proteolysis targeting chimera (PROTAC) and drug repurposing, which account for an increasing proportion of contemporary drug development[8-12].

Structural biology has always played an important role in drug discovery since it provides the most direct and visible atomic-level information on drug targets, and it can be applied to every step of preclinical drug development, including the identification and design of drug targets and the optimization of lead compounds[13]. Based on atomic resolution information about the active or regulatory sites of target proteins, the structural design of drugs becomes practical. Presently, there are three predominant techniques for the study of structural biology, namely, X-ray crystallography, nuclear magnetic resonance (NMR), and cryogenic electron microscopy (cryo-EM)[14]. X-ray crystallography usually provides structural information at the atomic level, which has obvious advantages for crystallizable macromolecules[15]. However, X-ray crystallography mostly covers protein molecules and molecular complexes with a size

*Correspondence: wangdp@mail.sustech.edu.cn; zhanghw@sustech.edu.cn

¹Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China

Full list of author information is available at the end of the article


of approximately 10–150 kD. As the yield of proper crystals becomes increasingly difficult with increasing molecular size, there are only a few crystal structures of target proteins beyond 150 kD and super-large protein complexes [16]. In addition, for membrane proteins, obtaining high-quality crystal structures is still full of uncertainties. On the other hand, without crystallization, NMR can directly analyze the structure of proteins in solution and provide valuable information about internal protein dynamics [17]. However, it requires the labelling of protein backbone and/or amino acid residues with NMR-sensitive isotopes and is limited to small proteins below 50 kD [18]. Cryo-EM is mainly used to analyze the structures of macromolecules larger than approximately 100 kD, and most cryo-EM structures with higher resolution than 3 Å are characterized as larger than 135 kD [16]. However, an increasing number of smaller proteins have been solved with the technical development of cryo-EM, such as Kirsten rat sarcoma virus, streptavidin, Lys-Asp-Glu-Leu receptor and receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein [19–22]. Cryo-EM determines the structure of macromolecular complexes and membrane proteins in solution with relatively small amounts of protein and without crystallization [23]. In addition, since proteins are highly dynamic in solution close to their native state, time-resolved cryo-EM can capture multiple conformations during the reaction, which is advantageous for structure elucidation [24].

The development of cryo-EM dates back to 1932, when the first electron microscopy was invented and predominantly used in materials science [25]. Thirty years later, the electron diffraction of protein crystals was first performed, which opened the door to the use of electron microscopy in the field of protein structure analysis [26]. With the development of a single-particle 3D reconstruction algorithm and the application of plunge-freezing techniques to biomacromolecules, cryo-EM has been gradually developed for structural biology since 1982 [27,28]. However, it could hardly resolve structures within 4 Å before 2013. With the development of algorithms and hardware, especially the introduction of direct electron detectors, the resolution of cryo-EM has been greatly improved [29–32]. The Nobel Prize in Chemistry 2017 has been awarded to three pioneers (Jacques Dubochet, Joachim Frank, and Richard Henderson) for their development of cryo-EM techniques. In 2020 alone, 1753 cryo-EM structures within 4 Å were published in the Protein Data Bank [33]. To the best of our knowledge, the highest resolution of proteins analyzed by cryo-EM has reached 1.2 Å, which indicates that cryo-EM has truly reached atomic resolution (Fig. 1a) [23,34,35].

The cryo-EM procedure is shown in Fig. 1b, mainly including sample preparation, cryo-EM grids setup and imaging, data collection and pre-processing, and three-dimensional (3D) map reconstruction as well as the subsequent model building and structure analysis. Despite the low resolution of early electron microscopy, cryo-EM has been used in combination with X-ray crystallography for drug development, including target identification and validation, since the 1990s [16]. In short, this approach did combine high-resolution crystal structure information with relatively low-resolution electron microscopic density maps, and through specialized adjustment and matching, it obtained information on difficult-to-crystallize macromolecular complexes. As cryo-EM has achieved atomic resolution, its role in the field of drug research and development has substantially increased in recent years. This review will illustrate how cryo-EM can facilitate the current drug discovery process through several examples in SBDD, FBDD, PROTAC, antibody drug development and drug repurposing. The combination of cryo-EM and other cutting-edge technologies such as artificial intelligence (AI) is also discussed, which may provide potential opportunities for further development of cryo-EM.

Application of cryo-EM in SBDD

SBDD is a streamlined drug design method based on molecular recognition of the 3D structure of ligands and target proteins, with the goal of finding and optimizing small-molecule drugs. Usually, the steps of SBDD include structure determination of the target protein, cavity identification, ligand database construction, ligand docking and lead discovery (Fig. 2a) [36]. SBDD is the current mainstream mode of drug development. It is usually combined with a computational-based fast virtual screening of large chemical libraries, which lowers the cost of the initial screenings. It can directly analyze the binding energy between drugs and targets, improve the hit rate of drug discovery, and assist rational drug design. Many drugs have reached the market through SBDD technology, such as captopril, an angiotensin-converting enzyme (ACE) inhibitor developed by Bristol Myers Squibb [37], which was the first to use enzyme-inhibitor structural information; saquinavir, which targets the human immunodeficiency virus protease, developed by Roche [38]; zanamivir, which is the neuraminidase inhibitor developed by Biota [39,40]; and the most famous breakpoint cluster region-proto-oncogene tyrosine-protein kinase inhibitor, imatinib [41], developed by Novartis for the treatment of leukaemia. However, the shortcomings of SBDD are also obvious, and obtaining high-resolution and complete structural information on protein



targets is a prerequisite for SBDD. Most of the target structures in SBDD are provided by X-ray crystallography. However, for membrane proteins and macromolecular complexes, obtaining high-quality crystal structures is particularly difficult[42,43]. With the rapid development of cryo-EM, this difficulty is being gradually resolved. Taking G-protein-coupled receptors (GPCRs) as an example, cryo-EM has shown incomparable effectiveness in SBDD[44].


GPCRs are the most abundant receptor membrane proteins on the cell surface and are targeted by approximately 30% of drugs on the market, including agonists and antagonists of GPCRs[45]. Although structural information of the GPCR targets for many marketed drugs has been obtained by X-ray crystallography, the highly dynamic nature of GPCRs makes it difficult to obtain high-quality crystals, so X-ray crystallography diffraction is powerful but challenging for many GPCR family members[46]. The natural advantages of cryo-EM for the structural elucidation of membrane proteins and highly dynamic proteins have facilitated the development of drugs targeting GPCRs[44,47-49]. Taking glucagon-like peptide-1 receptor (GLP-1R) protein as an example, cryo-EM has played an important role in the development of oral small molecule agonists of GLP-1R[50]. GLP-1R is a member of the class B GPCR family. The binding of GLP-1 peptide

to its receptor GLP-1R can activate GLP-1R to promote the proliferation of pancreatic β cells and increase insulin levels. Therefore, GLP-1R is one of the most effective targets for the treatment of type 2 diabetes[51]. GLP analogues such as exenatide, liraglutide, and semaglutide have been used in the clinical treatment of diabetes and obesity[52]. However, most of these peptide analogues are injection-based. In 2017, to rationally design small-molecule agonists that can be used orally, Jazayeri *et al.*[53] reported the crystal structure of GLP-1R binding to negative allosteric modulators, which provided structural information for GLP-1R drug development. However, it is difficult to obtain the activated conformation for crystallization and thus the binding site of the activator cannot be determined using X-ray crystallography. In 2020, Griffith *et al.*[54] improved the high-throughput screening of GLP-1R small-molecule agonists, carried out a series of optimizations to obtain lead compounds through structure-activity relationship, and finally obtained the small molecule agonist PF-06882961, which has high oral availability (Fig. 2b). At the same time, they analysed the electron microscopic structure of the complex of PF-06883365, an analogue of PF-06882961, with GLP-1R, revealed the interaction mechanism between the small-molecule agonists and GLP-1R, and identified the key factors of W33 and R380 in the activation process (Fig. 2c).

This study laid a foundation for the development of GLP-1R-based SBDD drugs and the optimization of lead compounds.

Additional examples for the application of cryo-EM in SBDD can be found in ion channels such as Transient Receptor Potential Cation Channel Subfamily A Member 1 (TRPA1)[55] and Transient Receptor Potential cation

channel subfamily V member 1[56], gamma-aminobutyric acid receptor[57,58], insulin receptor[59,60], as well as biased GPCR ligands like GLP-1 receptor-Gs complex[61], mu-opioid receptor[62], non-covalent TRPA1-biased agonist GNE551[63,64] and sphingosine-1-phosphate receptor 1[65].



Application of cryo-EM in FBDD

FBDD is one of the mainstream methods for lead compound discovery and involves obtaining structural information on the target, fragment screening, and fragment linking and modification, as shown in Fig. 3a[66]. Nuclear magnetic resonance, surface plasmon resonance, and other technologies can be used to screen for small-molecule fragments that have weak interactions with target proteins and then to optimize and connect active fragments based on their structural information to design lead compounds with higher activity. Unlike high-throughput screening to find macromolecules that fit multiple active pockets at the same time, FBDD aims to

find small fragments that fit a single active pocket. It requires a small compound library and has a high tolerance for pocket depth, even for some near-flat protein interaction pockets. FBDD technology also has a high success rate. However, the application of FBDD technology relies critically on the 3D structural information of the target protein, for which purified protein is essential[67]. Similar to SBDD, the acquisition of a 3D structure is usually the main factor limiting the development of FBDD technology. FBDD technology is in principle suitable mainly for proteins with multiple active sites and high molecular mass. The structural elucidation of suitable targets for FBDD using traditional crystal diffraction

techniques is challenging. Therefore, although FBDD has been in development for more than 20 years, only 6 FBDD drugs, vemurafenib, venetoclax, erdafitinib, pexidartinib, sotorasib and asciminib, have been approved for the market[68-70].

Cryo-EM has obvious advantages for the structural analysis of macromolecular proteins, and the resolution level is the main consideration for whether cryo-EM can contribute to FBDD. In 2020, Yip *et al.*[34] and Nakane *et al.*[35] independently reported the cryo-EM structure of apoferritin at 1.2 Å resolution, marking the development of this technology to a real atomic resolution level. Subsequently, Saur *et al.*[71] first explored the application of cryo-EM to FBDD with the β-galactosidase (Bgal) system and the cancer-related kinase pyruvate kinase isozymes M2 (PKM2) system as pilot studies. Bgal catalyses the hydrolysis of lactose to galactose and glucose[72]. The cryo-EM structure of Bgal shows that the protein has two deep binding pockets, which can bind L-ribose and 1-deoxyglactonojirimycin and are closed by a loop between G794-P803, in addition to a shallower pocket that can bind compounds such as β-D-thiogalactopyranoside (Fig. 3b). Saur *et al.*[71] used cryo-EM to analyse the 2.2–2.3 Å resolution complex structure of the above three small molecules, which clearly displayed the small-molecule structure of the binding site and the conformational changes of the active site protein, indicating that cryo-EM can be used to guide FBDD drug discovery (Fig. 3b). Next, they screened the small-molecule fragments of PKM2[71], which is a target kinase in cancer development and catalyses the conversion of phosphoenolpyruvate to pyruvate[73]. After structural analysis, the 2.6–3.2 Å complex structures of multiple compounds with PKM2 were determined, and the applicability of cryo-EM in FBDD was further demonstrated (Fig. 3c)[71].


Application of cryo-EM in PROTAC

Most small-molecule drugs need to bind to the active site or pocket of the target protein to function. However, for proteins that do not have suitable surface pockets, those drugs are powerless as they cannot bind to the target properly[74]. PROTAC is a drug development technology that utilizes the ubiquitin–proteasome system to degrade target proteins[75]. The PROTAC drug resembles a dumbbell structure and consists of three parts, an E3 ubiquitin ligase ligand, a target protein–ligand, and a special linker that connects the two active ligands. When the PROTAC drug enters the patient's body, the target protein–ligand and the E3 ubiquitin ligase ligand bind to the corresponding protein, thereby recruiting the E3 ubiquitin ligase to the vicinity of the target protein and ubiquitinating the target protein, resulting in the degradation

of the target protein by proteases (Fig. 4a)[76]. PROTAC technology not only can access some difficult accessible drug binding sites but also has the advantages of small doses, high selectivity and the ability to overcome drug resistance as it can eliminate the overexpressed or mutated targets[77,78].

The design of both active ligands and intermediate linkers of PROTAC is highly dependent on the structural information of the acting complex. MZ1 was the first PROTAC drug developed, with active ligands at both ends linked to the ubiquitin ligase von Hippel–Lindau (VHL) and the bromodomain and extra-terminal domain family protein bromodomain-containing protein 4 (BRD4) for cancer treatment (Fig. 4b)[78]. In addition, a study has shown that the small-molecule inhibitor MT1 can bind to BRD4, so based on the crystal structure of VHL-MZ1-BRD4, a new trivalent PROTAC drug has been developed that increased the effectiveness by 300-fold (Fig. 4c)[79], showing the importance of structural information in PROTAC drug development. Novartis combined X-ray crystallography and cryo-EM to resolve the anticancer mechanism of indisulam[80]. These studies showed that indisulam functions as a PROTAC drug and induces the degradation of mRNA spliceosome RNA-binding motif protein 39 (RBM39) by promoting the interaction between the E3 ubiquitin ligase DNA damage-binding protein 1 and cullin 4 associated factor 15 and RBM39, leading to cancer cell death (Fig. 4d). Although the electron microscope structure shows that indisulam specifically binds to RBM39, this approach is difficult to use for targeted therapy at other sites. However, the example of trivalent MZ1 shows that the structure-based modification of PROTAC drugs may expand the target range and improve target degradation.

In addition to cancer treatment, PROTAC drugs are promising to treat neurodegenerative diseases[81,82], antiviral infection[83,84], and antibacterial therapy[85]. For the treatment of neurodegenerative diseases, the main PROTAC targets are Tau protein and α-synuclein[86,87]. Peptide-based α-synuclein degraders have been experimentally shown to protect neurons from neurotoxicity induced by α-synuclein overexpression. The feasibility of antiviral PROTAC drugs has also been established in the study that degrade hepatitis C virus nonstructural protein 3/4A protease[88]. With the prevalence of the coronavirus disease 2019 (COVID-19), PROTAC technology has great potential for the targeted treatment of COVID-19 infection. The main proteases main protease and papain-like protease of the new coronavirus and RNA-dependent RNA polymerase are potential targets of PROTAC molecules[89]. Recently, Morreale *et al.*[85]




reported a BacPROTAC drug molecule and firstly explored the application of PROTACs in antibacterial activity, with analysis of the cryo-EM structure of AAA⁺unfoldase: caseinolytic protease P (ClpC:ClpP) in the apo state and drug binding state. ClpC:ClpP protease exists in gram-positive bacteria and recognizes phosphorylated arginine residues, which act as a degradation signal similar to the ubiquitin system in eukaryotic cells. The well-designed BacPROTAC molecule can bind to both the target protein monomeric streptavidin fused Kre and the ClpC:ClpP protease, and activate ClpC for target protein degradation (Fig. 4e).

Application of cryo-EM in antibody drug development

COVID-19 has a major impact on the health of human society. It is caused by a virus named SARS-CoV-2. Cryo-EM has played an important role in the research and development of novel antibodies and small molecule therapeutics targeting

SARS-CoV-2 infection[90]. Viral infection of human cells usually includes the following consecutive steps: I. recognition and absorption of the virus; II. virus fusion and disassembly; III. viral RNA release; IV. replication; V. translation; VI. assembly and maturation; VII. new virus release (Fig. 5a)[91]. Antibody drugs mainly work by blocking the adsorption and invasion of human cells by SARS-CoV-2. SARS-CoV-2 induces the expression of human angiotensin-converting enzyme 2 (ACE2) by producing interferon, which acts as a viral receptor to bind to the virus surface S protein and induce the transmembrane serine protease 2 (TMPRSS2) to mediate the rearrangement of the S protein, causing the fusion of the virus and the host cell plasma membrane. Therefore, the structural analysis of the S protein and ACE2 protein complex reveals important drug target sites and provides support for the elucidation of the immune escape mechanism of mutant strains and the development of antibody drugs[92].

Ambavirumab/romisevirumab combination therapy



is currently the only antibody drug approved by the State Food and Drug Administration of China. The two antibodies target different epitopes that bind to the S protein receptor and maintain therapeutic activity against a variety of mutant strains, including Omicron (Fig. 5b)[93-96]. The efficacy of the two antibodies is enhanced without competition and can effectively block the invasion of the infection of SARS-CoV-2. Among them, ambavirumab acts on the direct binding site of the spike (S) protein and ACE2, blocking the binding of the virus to ACE2, while romisevirumab acts on receptor binding site IV of the S protein to inhibit the fusion of the virus and the cell membrane. The structural information on the S-ACE2 complex and S-antibody complex obtained by cryo-EM provides important guidance for developing antibody-based drugs such as antibody screening, elucidating the mechanism of action, and structure optimization[96].

The acquisition of monoclonal neutralizing antibodies for the treatment of COVID-19 is usually obtained by screening and separation from the plasma of patients who have recovered

after being infected by the virus[97]. Shortening the screening and structure optimization time of highly efficient antibodies is a long-term goal of antibody development strategies. A recent study reported that the combination of cryo-EM and next-generation sequencing can quickly obtain key epitope information without isolating monoclonal antibodies, greatly shortening the time for antibody development[98]. The main process is shown in Fig. 5c. After immunizing animals or humans with labelled antigens to obtain antigen and polyclonal antibody complexes, cryo-EM is used to analyse the complex structure to confirm key epitopes and build epitope models. Considering the complexity of the manual matching process between density maps and amino acids, they also developed an algorithm tool for identifying antibody sequences based on density maps and matched and scored them with the antigen-binding specific B-cell next-generation sequencing database, thus quickly obtaining epitope information and monoclonal antibody structural models. Recently, the structures of B-cell receptors have also been resolved by cryo-EM, which promotes




Fig. 5 Application of cryo-EM in antibody drug development.

a. Replication cycle of SARS-CoV-2; b. Structure of S-ACE2 complex associates with the designation of ambavirumab and romisevirumab (EMDB: EMD-25760); c. Schematic diagram of cryo-EM and sequencing based antibody discovery. SARS-CoV2. Severe acute respiratory syndrome coronavirus 2; ACE2. Angiotensin-converting enzyme 2; TMPRESS2. Transmembrane serine protease 2; IFN. Type I interferon; RBD. Receptor-binding domain; RNA. Ribonucleic acid

the development of antibody-based therapeutics[99,100]. In conclusion, cryo-EM can guide and promote antibody drug screening, epitope research, and engineering transformation and is an effective tool for human health research.

Application of cryo-EM in drug failure and drug repurposing

Drug discovery is full of uncertainty. Most of the lead compounds or small-molecules obtained through high-throughput screening may be failed due to side effects. By revealing the mechanism of target-drug interactions, cryo-EM can reveal the potential reasons of drug failure or side effects[101]. For example, γ -secretase is considered to be an

important therapeutic target for Alzheimer's disease. Although a variety of small-molecule drugs targeting γ -secretase have been developed through high-throughput screening techniques, many of them have failed due to serious side effects. Yang *et al.*[102] reported the cryo-EM structures of γ -secretase in the substrate binding states [amyloid precursor protein (APP) and Notch, respectively] and 4 inhibitor binding states (semagacestat, avagacestat, L685458 in active site and E2012 in allosteric site) (Fig. 6a-c)[103]. Structural analysis showed that the main reason for the failure to develop γ -secretase inhibitors is that γ -secretase inhibitors lack specificity or have weak selectivity for APP and Notch proteolysis, thus cannot specifically inhibit APP binding[103]. It is worth noting

that although the development of several small-molecule drugs for the treatment of Alzheimer's disease has failed, small-molecule drugs such as nirogacestat have shown good efficacy against invasive fibroids, providing an example of drug repurposing[104]. Nirogacestat's anti-tumour effect is precisely its side effect of inhibiting Notch hydrolysis in Alzheimer's disease treatment, which enables a new application of the old drug. In fact, cryo-EM has now become a reliable tool for drug repurposing. Based on the PRISM drug reuse resource library developed by Corsello *et al.*[105], Chen *et al.*[106] used cryo-EM to investigate the potential value of three small-molecule compounds {anagrelide, nauclefine, and 6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-4,5-dihydropyridazin-3(2H)-one} as tumour suppressor drugs. They analysed the complex structures of phosphodiesterase 3A (PDE3A) and Schlafen protein family (SLFN) member SLFN12 with the three small molecules and found that these three small-molecule drugs can promote the complex formation of the two proteins and induce cellular apoptosis (Fig. 6d)[106]. Based on comprehensive considerations such as pharmacokinetics and safety, they finally modified anagrelide, which was originally used for the treatment of thrombocytosis, and obtained tumour inhibition effects in animal experiments.


Combination of cryo-EM and AI

AI is a broad interdisciplinary term generally referring to the ability of a computer to perform tasks commonly associated with human beings, which is learning and problem-solving, rooted in logic, statistics, neuroscience and computer engineering[107]. AI and its subdiscipline machine learning (ML) are now playing increasingly essential roles in health care-related fields such as drug discovery[108,109]. AI techniques, especially ML, could contribute to almost every aspect of drug discovery, including the identification of new drug targets, computer-aided drug screening, synthetic accessibility, and retrosynthesis predictions that aid synthesis planning as well as various ML-based methods of drug toxicity prediction[110-113]. Most importantly, AI-based protein structure prediction methods such as AlphaFold2 are expected to have a dramatic impact on drug discovery by aiding the structure determination and molecular mechanism analysis of human diseases[114]. Lupas *et al.*[115] have reported the successful application of AlphaFold2 to the crystal structure determination of an archaeal transmembrane receptor, which they had failed to solve for almost a decade because phasing problems and the lack of a template hindered the performance of molecular replacement, although they had diffraction data with good quality. The AlphaFold2-produced template solved

the problem with extremely high accuracy. Recently, Fontana *et al.*[116] reported the structure of the cytoplasmic ring of the nucleus pore complex by integrative cryo-EM and AlphaFold. The nuclear pore complex (NPC) is the molecular conduit located in the nuclear membrane of eukaryotic cells that mediates the exchange of biomolecules between the nucleus and the cytosol. To better understand the organization, dynamics and complexity of NPCs, they reconstructed the cytoplasmic ring map of *Xenopus laevis* NPC at 6–7 Å resolution and used AlphaFold to predict the structures of the individual subunits and the complex structures to guide model fitting of the CR map. This case gives an example of integrative cryo-EM and AlphaFold as a general tool to obtain more sophisticated models from medium-resolution density maps. In addition, AI has facilitated the advance of cryo-EM data collection[117] and data processing[118,119]. With the technique of reinforcement learning (RL), the algorithm cryoRL has been used to solve the path planning problem to maximize data quality and minimize human intervention during data collection[117]. Topaz is an efficient and accurate particle-picking program based on neural networks and ML that has shown merits in conventionally challenged proteins with small, nonglobal and asymmetric particles and improving the signal-to-noise ratio in cryo-EM image processing[118,119]. Currently, the automation, throughput and resolution level are the predominant obstacles restricting the application of cryo-EM in drug development[120]. AI might be the key to solving these problems, and the integration of cryo-EM and AI techniques promise to substantially accelerate drug development.

Conclusions

Structural biology has always played an important guiding role in drug development. With the development of new techniques, the role of cryo-EM in drug development strategies such as SBDD, FBDD, and PROTAC has become increasingly important. However, it cannot be ignored that cryo-EM still has certain limitations in drug research and development, mainly in the following three aspects. Firstly, cryo-EM still presents certain technical barriers in the analysis of small proteins but there are many efforts taken which include the introduction of new electron optical apparatuses like energy filter, Cs-corrector, and Volta phase plate, as well as the utilization of scaffolds which increases the molecular weight of the target protein. Lys-Asp-Glu-Leu receptor, which is about 23 kD, is the smallest membrane protein resolved by cryo-EM with sufficient map density for *de novo* model building[19]. Second, the resolution of cryo-EM still needs



improvement. Although the current highest resolution reached 1.2 Å, most of the reported cryo-EM structures are still at the 3–4 Å level, and therefore the structural information on drug molecule binding target sites usually needs to be combined with higher resolution protein structures obtained from

X-ray crystallography. Finally, cryo-EM data collection and processing lag a bit behind X-ray crystallographic diffraction. But it is worth noting that the situation is getting better and there are now dramatic improvements in both automated data collection using programs such as serialEM[121], multigrad

cartridges in state of the art microscopes, as well as on the fly data processing such as cryoSPARC live[122]. Modern AI techniques may help overcome those limitations of cryo-EM in drug development in the near future.

Abbreviations

ACE2: Angiotensin-converting enzyme 2; AI: Artificial intelligence; APP: Amyloid precursor protein; Bgal: β -Galactosidase; BRD4: Bromodomain-containing protein 4; ClpC: AAA+unfoldase; ClpP: Caseinolytic protease P; COVID-19: Coronavirus disease 2019; Cryo-EM: Cryo-electron microscopy; FBDD: Fragment-based drug discovery; GLP-1R: Glucagon-like peptide-1 receptor; GPCR: G-protein-coupled receptor; ML: Machine learning; NMR: Nuclear magnetic resonance; NPC: Nuclear pore complex; PKM2: Pyruvate kinase isozymes M2; PROTAC: Proteolysis targeting chimera; RBM39: RNA-binding motif protein 39; RL: Reinforcement learning; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SBDD: Structure-based drug design; SLFN: Schlafen protein family; VHL: Von Hippel-Lindau.

Acknowledgements

Not applicable.

Author contributions

DPW and HWZ designed the review. KFZ and HWZ prepared the draft. CY, YMD, KLS, XKZ, HV, XDJ, YZG and QFZ reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by the National Natural Science Foundation of China (NSFC, 31900046, 81972085, 82172465 and 32161133022), the Guangdong Provincial Key Laboratory of Advanced Biomaterials (2022B1212010003), the National Science and Technology Innovation 2030 Major Program (2022ZD0211900), the Shenzhen Key Laboratory of Computer Aided Drug Discovery (ZDSYS20201230165400001), the Chinese Academy of Science President's International Fellowship Initiative (PIFI) (2020FSB0003), the Guangdong Retired Expert (granted by Guangdong Province), the Shenzhen Pengcheng Scientist, NSFC-SNSF Funding (32161133022), AlphaMol & SIAT Joint Laboratory, Shenzhen Government Top-talent Working Funding and Guangdong Province Academician Work Funding.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Horst Vogel is the cofounder of AlphaMol Science Ltd. The remaining authors declare no competing interests.

Author details

¹Department of Biomedical Engineering, Southern University of

Science and Technology, Shenzhen 518055, Guangdong, China.

²Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.

³Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. ⁴Center for Protein Science and Crystallography, School of Life Sciences, Faculty of Science, Chinese University of Hong Kong, Hong Kong 999077, China. ⁵Interdisciplinary Center for Brain Information, the Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China.

⁶Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China. ⁷Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen 518055, Guangdong, China. ⁸Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China. ⁹State Key Lab for Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510275, China. ¹⁰Cryo-EM Facility Center, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China. ¹¹Department of Orthopedics, Shenzhen Intelligent Orthopaedics and Biomedical Innovation Platform, Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518000, Guangdong, China. ¹²Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.

References

1. Li JWH, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier?. *Science*. 2009;325(5937):161–5.
2. Lobanovska M, Pilla G. Penicillin's discovery and antibiotic resistance: lessons for the future?. *Yale J Biol Med*. 2017;90(1):135–45.
3. Azevedo-Barbosa H, Dias DF, Franco LL, Hawkes JA, Carvalho DT. From antibacterial to antitumour agents: a brief review on the chemical and medicinal aspects of sulfonamides. *Mini Rev Med Chem*. 2020;20(19):2052–66.
4. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. *Expert Opin Drug Saf*. 2007;6(5):609–21.
5. Ma N, Zhang Z, Liao F, Jiang T, Tu Y. The birth of artemisinin. *Pharmacol Ther*. 2020;216:107658.
6. Gershell LJ, Atkins JH. A brief history of novel drug discovery technologies. *Nat Rev Drug Discov*. 2003;2(4):321–7.
7. Pina AS, Hussain A, Roque ACA. An historical overview of drug discovery. *Methods Mol Biol*. 2009;572:3–12.
8. Finn J. Application of SBDD to the discovery of new antibacterial drugs. *Methods Mol Biol*. 2012;841:291–319.
9. Bissaro M, Sturlese M, Moro S. The rise of molecular simulations in fragment-based drug design (FBDD): an overview. *Drug Discov Today*. 2020;25(9):1693–701.
10. Gironda-Martínez A, Donckele EJ, Samain F, Neri D. DNA-encoded chemical libraries: a comprehensive review with successful stories and future challenges. *ACS Pharmacol Transl Sci*. 2021;4(4):1265–79.
11. Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. *Cell Biochem Funct*. 2019;37(1):21–30.
12. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations.

- Nat Rev Drug Discov. 2019;18(1):41–58.
13. Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, Maroyi A, *et al.* Natural products for drug discovery in the 21st century: innovations for novel drug discovery. *Int J Mol Sci.* 2018;19(6):1578.
 14. Cramer P. Structural molecular biology—a personal reflection on the occasion of John Kendrew’s 100th birthday. *J Mol Biol.* 2017;429(17):2603–10.
 15. Shi Y. A glimpse of structural biology through X-ray crystallography. *Cell.* 2014;159(5):995–1014.
 16. Wang HW, Wang JW. How cryo-electron microscopy and X-ray crystallography complement each other. *Protein Sci.* 2017;26(1):32–9.
 17. Rankin NJ, Preiss D, Welsh P, Burgess KE, Nelson SM, Lawlor DA, *et al.* The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. *Atherosclerosis.* 2014;237(1):287–300.
 18. Pedrini B, Serrano P, Mohanty B, Geralt M, Wüthrich K. NMR-profiles of protein solutions. *Biopolymers.* 2013;99(11):825–31.
 19. Wu X, Rapoport TA. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies). *Proc Natl Acad Sci U S A.* 2021;118(41):e2115001118.
 20. Fan X, Wang J, Zhang X, Yang Z, Zhang JC, Zhao L, *et al.* Single particle cryo-EM reconstruction of 52 kD streptavidin at 3.2 Angstrom resolution. *Nat Commun.* 2019;10(1):2386.
 21. Castells-Graells R, Meador K, Arbing MA, Sawaya MR, Gee M, Cascio D, *et al.* Rigidified scaffolds for 3 angstrom resolution cryo-EM of small therapeutic protein targets. *BioRxiv.* 2022. <https://doi.org/10.1101/2022.09.18.508009>.
 22. Liu Y, Gonen S, Gonen T, Yeates TO. Near-atomic cryo-EM imaging of a small protein displayed on a designed scaffolding system. *Proc Natl Acad Sci U S A.* 2018;115(13):3362–7.
 23. Bai XC, McMullan G, Scheres SHW. How cryo-EM is revolutionizing structural biology. *Trends Biochem Sci.* 2015;40(1):49–57.
 24. Frank J. Time-resolved cryo-electron microscopy: recent progress. *J Struct Biol.* 2017;200(3):303–6.
 25. Knott G, Genoud C. Is EM dead?. *J Cell Sci.* 2013;126(Pt 20):4545–52.
 26. Taylor KA, Glaeser RM. Electron diffraction of frozen, hydrated protein crystals. *Science.* 1974;186(4168):1036–7.
 27. Dubochet J, Chang JJ, Freeman R, Lepault J, McDowell AW. Frozen aqueous suspensions. *Ultramicroscopy.* 1982;10(1–2):55–61.
 28. Frank J. Averaging of low exposure electron micrographs of non-periodic objects. *Ultramicroscopy.* 1975;1(2):159–62.
 29. Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. *J Mol Biol.* 2003;333(4):721–45.
 30. Liao M, Cao E, Julius D, Cheng Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. *Nature.* 2013;504(7478):107–12.
 31. Bai XC, Fernandez IS, McMullan G, Scheres SH. Ribosome structures to near-atomic resolution from thirty thousand cryo-EM particles. *Elife.* 2013;2:e00461.
 32. Li X, Mooney P, Zheng S, Booth CR, Braunfeld MB, Gubbens S, *et al.* Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. *Nat Methods.* 2013;10(6):584–90.
 33. Robertson MJ, Meyerowitz JG, Skiniotis G. Drug discovery in the era of cryo-electron microscopy. *Trends Biochem Sci.* 2022;47(2):124–35.
 34. Yip KM, Fischer N, Paknia E, Chari A, Stark H. Atomic-resolution protein structure determination by cryo-EM. *Nature.* 2020;587(7832):157–61.
 35. Nakane T, Kotecha A, Sente A, McMullan G, Masiulis S, Brown P, *et al.* Single-particle cryo-EM at atomic resolution. *Nature.* 2020;587(7832):152–6.
 36. Wang X, Song K, Li L, Chen L. Structure-based drug design strategies and challenges. *Curr Top Med Chem.* 2018;18(12):998–1006.
 37. Nemeč K, Schubert-Zsilavecz M. From teprotide to captopril. Rational design of ACE inhibitors. *Pharm Unserer Zeit.* 2003;32(1):11–6.
 38. La Porte CJ. Saquinavir, the pioneer antiretroviral protease inhibitor. *Expert Opin Drug Metab Toxicol.* 2009;5(10):1313–22.
 39. Air GM. Influenza neuraminidase. *Influ Other Respir Viruses.* 2012;6(4):245–56.
 40. Chapple KJ, Hendrick AE, McCarthy MW. Zanamivir in the treatment and prevention of influenza. *Ann Pharmacother.* 2000;34(6):798–801.
 41. Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. *Nat Rev Drug Discov.* 2021;20(7):551–69.
 42. Garavito RM, Picot D, Loll PJ. Strategies for crystallizing membrane proteins. *J Bioenerg Biomembr.* 1996;28(1):13–27.
 43. Melnikov I, Svensson O, Bourenkov G, Leonard G, Popov A. The complex analysis of X-ray mesh scans for macromolecular crystallography. *Acta Crystallogr D Struct Biol.* 2018;74(Pt 4):355–65.
 44. García-Nafria J, Tate CG. Cryo-electron microscopy: moving beyond X-ray crystal structures for drug receptors and drug development. *Annu Rev Pharmacol Toxicol.* 2020;60:51–71.
 45. Congreve M, Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. *Br J Pharmacol.* 2010;159(5):986–96.
 46. Ciancetta A, Jacobson KA. Breakthrough in GPCR crystallography and its impact on computer-aided drug design. *Methods Mol Biol.* 2018;1705:45–72.
 47. Zhang X, Johnson RM, Drulyte I, Yu L, Kotecha A, Danev R, *et al.* Evolving cryo-EM structural approaches for GPCR drug discovery. *Structure.* 2021;29(9):963–74.e6.
 48. Congreve M, de Graaf C, Swain NA, Tate CG. Impact of GPCR structures on drug discovery. *Cell.* 2020;181(1):81–91.
 49. Liang YL, Khoshouei M, Radjainia M, Zhang Y, Glukhova A, Tarrasch J, *et al.* Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. *Nature.* 2017;546(7656):118–23.
 50. Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, *et al.* Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. *Nature.* 2017;546(7657):248–53.
 51. Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. *Br J Pharmacol.* 2012;166(1):27–41.
 52. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. *Mol Metab.* 2021;46:101102.
 53. Jazayeri A, Rappas M, Brown AJH, Kean J, Errey JC, Robertson NJ, *et al.* Crystal structure of the GLP-1 receptor bound to a peptide agonist. *Nature.* 2017;546(7657):254–8.
 54. Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, *et al.* A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. *J Med Chem.* 2022;65(12):8208–26.

55. Paulsen CE, Armache JP, Gao Y, Cheng Y, Julius D. Structure of the TRPA1 ion channel suggests regulatory mechanisms. *Nature*. 2015;520(7548):511–7.
56. Yang F, Xiao X, Cheng W, Yang W, Yu P, Song Z, *et al.* Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. *Nat Chem Biol*. 2015;11(7):518–24.
57. Laverty D, Desai R, Uchański T, Masiulis S, Stec WJ, Malinauskas T, *et al.* Cryo-EM structure of the human $\alpha 1\beta 3\gamma 2$ GABA(A) receptor in a lipid bilayer. *Nature*. 2019;565(7740):516–20.
58. Masiulis S, Desai R, Uchański T, Serna Martin I, Laverty D, Karia D, *et al.* GABA(A) receptor signalling mechanisms revealed by structural pharmacology. *Nature*. 2019;565(7740):454–9.
59. Park J, Li J, Mayer JP, Ball KA, Wu J, Hall C, *et al.* Activation of the insulin receptor by an insulin mimetic peptide. *Nat Commun*. 2022;13(1):5594.
60. Uchikawa E, Choi E, Shang G, Yu H, Bai XC. Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor-ligand complex. *Elife*. 2019;8:e48630.
61. Liang YL, Khoshouei M, Glukhova A, Furness SGB, Zhao P, Clydesdale L, *et al.* Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. *Nature*. 2018;555(7694):121–5.
62. Zamorano CA, Bruchas MR. Visualizing ligand bias at the Mu-opioid receptor. *Cell*. 2022;185(23):4251–3.
63. Fine M, Li X. Insights into the irritating mechanisms of TRPA1 revealed by cryo-EM. *Neuron*. 2021;109(2):194–6.
64. Liu C, Reese R, Vu S, Rouge L, Shields SD, Kakiuchi-Kiyota S, *et al.* A non-covalent ligand reveals biased agonism of the TRPA1 ion channel. *Neuron*. 2021;109(2):273–84.e4.
65. Xu Z, Ikuta T, Kawakami K, Kise R, Qian Y, Xia R, *et al.* Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism. *Nat Chem Biol*. 2022;18(3):281–8.
66. Li Q, Kang C. Perspectives on fragment-based drug discovery: a strategy applicable to diverse targets. *Curr Top Med Chem*. 2021;21(13):1099–112.
67. Kashyap A, Singh PK, Silakari O. Counting on fragment based drug design approach for drug discovery. *Curr Top Med Chem*. 2018;18(27):2284–93.
68. Ruzic D, Djokovic N, Nikolic K. Fragment-based drug design of selective HDAC6 inhibitors. *Methods Mol Biol*. 2021;2266:155–70.
69. Bon M, Bilsland A, Bower J, Mcaulay K. Fragment-based drug discovery the importance of high-quality molecule libraries. *Mol Oncol*. 2022;16(21):3761–77.
70. Deeks ED. Asciminib: first approval. *Drugs*. 2022;82(2):219–26.
71. Saur M, Hartshorn MJ, Dong J, Reeks J, Bunkoczi G, Jhoti H, *et al.* Fragment-based drug discovery using cryo-EM. *Drug Discov Today*. 2020;25(3):485–90.
72. Huber RE, Kurz G, Wallenfels K. A quantitation of the factors which affect the hydrolase and transgalactosylase activities of β -galactosidase (*E. coli*) on lactose. *Biochemistry*. 1976;15(9):1994–2001.
73. Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, *et al.* PKM2 and cancer: the function of PKM2 beyond glycolysis. *Oncol Lett*. 2016;11(3):1980–6.
74. Zheng X, Gan L, Wang E, Wang J. Pocket-based drug design: exploring pocket space. *AAPS J*. 2013;15(1):228–41.
75. Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. *Curr Opin Chem Biol*. 2019;50:111–9.
76. Zeng S, Huang W, Zheng X, Liyan C, Zhang Z, Wang J, *et al.* Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. *Eur J Med Chem*. 2021;210:112981.
77. Burke MR, Smith AR, Zheng G. Overcoming cancer drug resistance utilizing PROTAC technology. *Front Cell Dev Biol*. 2022;10:872729.
78. Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, *et al.* Structural basis of PROTAC cooperative recognition for selective protein degradation. *Nat Chem Biol*. 2017;13(5):514–21.
79. Imaide S, Riching KM, Makukhin N, Vetma V, Whitworth C, Hughes SJ, *et al.* Trivalent PROTACs enhance protein degradation *via* combined avidity and cooperativity. *Nat Chem Biol*. 2021;17(11):1157–67.
80. Bussiere DE, Xie L, Srinivas H, Shu W, Burke A, Be C, *et al.* Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. *Nat Chem Biol*. 2020;16(1):15–23.
81. Kargbo RB. PROTAC degradation of IRAK4 for the treatment of neurodegenerative and cardiovascular diseases. *ACS Med Chem Lett*. 2019;10(9):1251–2.
82. Jiang X, Zhou J, Wang Y, Liu X, Xu K, Xu J, *et al.* PROTACs suppression of GSK-3 β , a crucial kinase in neurodegenerative diseases. *Eur J Med Chem*. 2021;210:112949.
83. Verma R. Exploiting ubiquitin ligases for induced target degradation as an antiviral strategy. *Adv Exp Med Biol*. 2021;1322:339–57.
84. Desantis J, Mercorelli B, Celegato M, Croci F, Bazzacco A, Baroni M, *et al.* Indomethacin-based PROTACs as pan-coronavirus antiviral agents. *Eur J Med Chem*. 2021;226:113814.
85. Morreale FE, Kleine S, Leodolter J, Junker S, Hoi DM, Ovchinnikov S, *et al.* BacPROTACs mediate targeted protein degradation in bacteria. *Cell*. 2022;185(13):2338–53.e18.
86. Kargbo RB. Treatment of Alzheimer's by PROTAC-Tau protein degradation. *ACS Med Chem Lett*. 2019;10(5):699–700.
87. Kargbo RB. PROTAC compounds targeting α -synuclein protein for treating neurodegenerative disorders: Alzheimer's and Parkinson's diseases. *ACS Med Chem Lett*. 2020;11(6):1086–7.
88. de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, *et al.* Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. *Nat Commun*. 2019;10(1):3468.
89. Shaheer M, Singh R, Sobhia ME. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2. *J Biomol Struct Dyn*. 2021;40(21):10905–17.
90. Kim HU, Jung HS. Cryo-EM as a powerful tool for drug discovery: recent structural based studies of SARS-CoV-2. *Appl Microsc*. 2021;51(1):13.
91. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol*. 2022;23(1):3–20.
92. Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, *et al.* Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. *Science*. 2020;369(6508):1261–5.
93. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, *et al.* Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science*. 2020;369(6504):731–6.
94. Ge J, Wang R, Ju B, Zhang Q, Sun J, Chen P, *et al.* Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. *Nat Commun*. 2021;12(1):250.
95. Taylor PC, Adams AC, Hufford MM, De La Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat Rev Immunol*. 2021;21(6):382–93.
96. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K,

- et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature*. 2022;602(7898):664–70.
97. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. *Clin Infect Dis*. 2020;71(16):2027–34.
 98. Antanasijevic A, Bowman CA, Kirchdoerfer RN, Cottrell CA, Ozorowski G, Upadhyay AA, et al. From structure to sequence: antibody discovery using cryoEM. *Sci Adv*. 2022;8(3):eabk2039.
 99. Su Q, Chen M, Shi Y, Zhang X, Huang G, Huang B, et al. Cryo-EM structure of the human IgM B cell receptor. *Science*. 2022;377(6608):875–80.
 100. Ma X, Zhu Y, Dong D, Chen Y, Wang S, Yang D, et al. Cryo-EM structures of two human B cell receptor isotypes. *Science*. 2022;377(6608):880–5.
 101. Yang G, Zhou R, Shi Y. Cryo-EM structures of human γ -secretase. *Curr Opin Struct Biol*. 2017;46:55–64.
 102. Yang G, Zhou R, Zhou Q, Guo X, Yan C, Ke M, et al. Structural basis of Notch recognition by human γ -secretase. *Nature*. 2019;565(7738):192–7.
 103. Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of γ -secretase inhibition and modulation by small molecule drugs. *Cell*. 2021;184(2):521–33.e14.
 104. Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (Review). *Int J Mol Med*. 2020;45(2):279–97.
 105. Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. *Nat Cancer*. 2020;1(2):235–48.
 106. Chen J, Liu N, Huang Y, Wang Y, Sun Y, Wu Q, et al. Structure of PDE3ASLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells. *Nat Commun*. 2021;12(1):6204.
 107. Howard J. Artificial intelligence: implications for the future of work. *Am J Ind Med*. 2019;62(11):917–26.
 108. Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing drug discovery via artificial intelligence. *Trends Pharmacol Sci*. 2019;40(8):592–604.
 109. Khan SR, Al Rijjal D, Piro A, Wheeler MB. Integration of AI and traditional medicine in drug discovery. *Drug Discov Today*. 2021;26(4):982–92.
 110. Medicine and the computer. *N Engl J Med*. 1971;284(12):677–8.
 111. McComb M, Bies R, Ramanathan M. Machine learning in pharmacometrics: opportunities and challenges. *Br J Clin Pharmacol*. 2022;88(4):1482–99.
 112. Pu L, Naderi M, Liu T, Wu HC, Mukhopadhyay S, Brylinski M. eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates. *BMC Pharmacol Toxicol*. 2019;20(1):2.
 113. Zhang J, Norinder U, Svensson F. Deep learning-based conformal prediction of toxicity. *J Chem Inf Model*. 2021;61(6):2648–57.
 114. Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Zidek A, et al. Highly accurate protein structure prediction for the human proteome. *Nature*. 2021;596(7873):590–6.
 115. Lupas AN, Pereira J, Alva V, Merino F, Coles M, Hartmann MD. The breakthrough in protein structure prediction. *Biochem J*. 2021;478(10):1885–90.
 116. Fontana P, Dong Y, Pi X, Tong AB, Hecksel CW, Wang L, et al. Structure of cytoplasmic ring of nuclear pore complex by integrative cryo-EM and AlphaFold. *Science*. 2022;376(6598):eabm9326.
 117. Li Y, Fan Q, Cohn J, Demers V, Lee JY, Yip L, et al. Optimized path planning surpasses human efficiency in cryo-EM imaging. *bioRxiv*. 2022. <https://doi.org/10.1101/2022.06.17.496614>.
 118. Bepler T, Morin A, Rapp M, Brasch J, Shapiro L, Noble AJ, et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Nat Methods*. 2019;16(11):1153–60.
 119. Bepler T, Kelley K, Noble AJ, Berger B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. *Nat Commun*. 2020;11(1):5208.
 120. Ceska T, Chung CW, Cooke R, Phillips C, Williams PA. Cryo-EM in drug discovery. *Biochem Soc Trans*. 2019;47(1):281–93.
 121. Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. *J Struct Biol*. 2005;152(1):36–51.
 122. Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods*. 2017;14(3):290–6.

<https://doi.org/10.1186/s40779-023-00446-y>

Cite this article as: Zhu KF, Yuan C, Du YM, Sun KL, Zhang XK, Vogel H, et al. Applications and prospects of cryo-EM in drug discovery. *Mil Med Res*. 2023;10(1):10.